Mutual Funds increased stake in 14 pharma stocks in Q4FY25; do you own any?

Shares of pharma sector companies continue to remain on investor's radar as the sector awaits the anticipated US tariff announcements on pharma imports. While increasing tariffs by 10 per cent across-goods, the US President Donald Trump said that tariffs on pharma imports will be announced at a later date. The US President stated that he would impose "major" tariffs on pharmaceuticals in the near future, a move that could end decades of low-cost global trade in medicines. However, recent reports suggest thae Donald Trump was open to offer some exemptions to his 10 per cent baseline tariff, to select selectors including auto ancillaries and electronics among others. As the suspense over the US tariffs on the pharma industry continues, shares of pharmaceutical companies have recovered notable ground in the month of April thus far. As many as 82 pharma stocks outperformed the Nifty Pharma and Nifty Healthcare indices - gaining over 4 per cent; with the top 3 rallying more than 50 per cent. READ MORE Meanwhile, as per the shareholding pattern at the end of March 2025 quarter domestic mutual funds (MFs) have increased stake in a total of 38 pharma and healthcare related stocks. Out of which, MFs increased stake in 14 pharma stocks by more than 10 per cent each. Analysts believe that pharma as a sector is well-positioned to counter any potential impact of tariff hikes, as it can easily pass on the additional costs by hiking prices of the medicines. Kranthi Bathini, Director-Equity strategy at WealthMills securities says that medicines have an inelastic demand, so even if there are tariffs imposed on the sector it could not have much impact on the industry in the longer-run. Additionally, pharma as a sector has shown some signs of recovery in the last one year, after a prolonged period of under-performance in the preceding two years. At present levels, valuations look attractive for the pharma sector, hence it is attracting buying interest, Kranthi added. Data from ACE Equity shows that MFs raised stake in Brooks Laboratories by 156 per cent, from 3.86 per cent at the end of December 2024 quarter to 9.9 per cent at the end of March 2025 quarter. Similarly, MFs increased stake in Onesource Speciality, Indegene and Zota Heath Care by 86.8 per cent, 57.9 per cent and 50 per cent, respectively. MFs now own up to 8.32 per cent, 2.65 per cent and 0.03 per cent, respectively, in each of the above mentioned companies. Among prominent names, MFs raised shareholding in Granules India from 10.39 per cent to 11.57 per cent. In Dr. Reddy's Laboratories from 11.14 per cent to 12.89 per cent; Neuland Laboratories from 6.29 per cent to 7.43 per cent; Aarti Drugs from 7.78 per cent to 8.75 per cent and GlaxoSmithKline Pharma from 4.96 per cent to 5.17 per cent. These apart, MFs have also hiked stake in other notable pharma companies such as - Marksans Pharma, Wockhardt, Cipla, Piramal Pharma, Glenmark Pharma, Zydus Lifesciences, Divi's Laboratories, Aurobindo Pharma, Biocon, Lupin and Pfizer by 3 - 7 per cent. On the other hand, MFs have decreased holdings in Supriya Lifescience, Vimta Labs and Suven Life Sciences by over 100 per cent each. Strides Pharma, Emcure Pharmaceuticals, Laurus Labs, AstraZeneca Pharma, Concord Biotech, Gland Pharma, Unichem Laboratories and Mankind Pharma were among the prominent stocks wherein MFs stake has declined.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Hindustan Times

17 minutes ago

• Hindustan Times

Latvian president believes NATO will overcome obstacles, meet 5% goal

By Andrius Sytas Latvian president believes NATO will overcome obstacles, meet 5% goal RIGA, - Latvia's president expressed confidence NATO would agree to a new higher defence spending target demanded by U.S. President Donald Trump, despite Spanish objections, saying the alliance had little choice given the growing threat from Russia. Spain on Thursday asked to opt out of the plan to increase members' defence spending to 5% of their gross domestic product, as requested by Trump, a move which could derail next week's NATO summit at the Hague. Any agreement to raise defence spending needs unanimous approval by the 32 member states. Latvian President Edgars Rinkevics told Reuters on Friday he understood why countries further from Russia might have difficulties convincing their voters to spend more on defence. But he said the need was pressing. 'I do hope there is the understanding in Madrid that this is a critical time for the Alliance, both when it comes to its defence capabilities, but also to the Trans-Atlantic relationship,' he said in an interview in Riga. 'I think that they don't have much of a choice,' he added. At an estimated 1.28% of GDP, Spain had the lowest proportion of expenditure on defence in the alliance last year, according to NATO estimates. Latvia and fellow Baltic states Lithuania and Estonia are urgently ramping up their militaries, fearing that their neighbour and former overlord Russia could push on from its 2022 invasion of Ukraine to take more territory. They spent more than 3% of GDP on defence this year, and have committed to top 5% for the next few years. "We are saying that we need to spend as soon as possible now in order to avoid a worst-case scenario, spending much more later," Rinkevics said. "While Russia is stuck in Ukraine, that possibility of a direct military attack is not very high," he said. "But it may change very, very quickly ... if a development in Ukraine leads Russian leadership to believe that NATO is weak, that Ukraine is defeated, that NATO is divided". This article was generated from an automated news agency feed without modifications to text.

Mint

24 minutes ago

• Mint

'Not just one challenge; Accenture clients are facing everything, all at once'

Accenture Plc. on Friday said Fortune 500 companies unnerved by global conflicts and tariff wars are holding back technology spending, prompting it to issue a muted guidance for the current quarter. The subdued guidance rattled investors, with shares of the world's largest information technology outsourcer trading 7.6% at $283 at 8:30pm Indian time. The guidance could signal further challenges for India's $283 billion IT services companies, which started their fiscal year on a weak note. Accenture recorded revenue growth—6% sequentially and 7.7% annually—to $17.73 billion, but the company expects slower days ahead. The company expects revenue of $17-17.6 billion in the fourth quarter (March to May). Accenture follows a September-August financial year while Indian IT firms follow an April-March calendar. The company cut its headcount by 10,000 to end with 790,000 employees last quarter. Accenture flagged the threat to businesses from US president Donald Trump's tariffs and policy flip-flops, coupled with the Iran-Israel conflict. This implies that new business might be harder to get for Indian IT outsourcers, who issue their quarterly earnings next month. 'As we shared last quarter, we continue to see a significantly elevated level of uncertainty in the global economic and geopolitical environment as compared to calendar year 2024,' said Julie Sweet, chair and chief executive of Accenture, during the company's post-earnings conference call. The IT services company did not raise the upper end of its growth guidance of 7% for the full year, reflecting its views on the macroeconomic environment. Accenture expects to spend up to $1.5 billion on acquisitions during this fiscal. The management said that about 3% of its full-year growth of 7% is expected from acquisitions. Sweet added that clients were faced with multiple challenges at once. 'In every boardroom and every industry, our clients are not facing a single challenge—They are facing everything at once, economic volatility, geopolitical complexity, major shifts in customer behavior,' she said. Accenture's dim outlook stokes further uncertainty for India's five largest software service providers including Tata Consultancy Services Ltd, Infosys Ltd, HCL Technologies Ltd, Wipro Ltd and Tech Mahindra Ltd, which struggled to bag deals valued at over $1 billion last fiscal. A dwindling large order book is further expected to raise questions on the readiness of Indian IT to weather the macroeconomic storm. A third of Accenture's quarterly revenue came from its software products business. Sweet added that the pause in tech spending was short and that clients wanted to be the first to adopt artificial intelligence (AI). 'I am talking to CEOs every day, and you know, there was this whole narrative about a pause and sitting on the sidelines. And I would tell you, it was very short. Our clients have moved from pause to focus and leapfrog,' said Sweet. Earlier, an analyst said Accenture could face difficulty in bagging deals in the second half of the fiscal. 'Additionally, we believe Accenture faces difficult bookings compares in 2HFY25, which creates a tricky setup in a tepid backdrop,' said BMO Capital Markets analyst Keith Bachman, in a note dated 18 June. Bachman added that 'the economic environment has modestly weakened in aggregate,' signalling that times might be tougher for IT outsourcers as clients hold back their tech spending. However, a bright spot in the company's report card was its GenAI (generative artificial intelligence) order book. Accenture secured $1.5 billion in new GenAI bookings in the quarter, which comprised almost 8% of its overall order bookings of $19.7 billion for the quarter. In the same quarter, Accenture got revenues of $700 million from Gen AI projects. So far, since September 2023, the company has taken its total tally of orders in Gen AI to $7.1 billion. For context, Accenture's total order bookings from GenAI alone is more than the FY25 revenue of Tech Mahindra Ltd, India's fifth-largest software services company. Tech Mahindra ended last fiscal with $6.26 billion in revenue. Accenture was the first software services company to state its Gen AI deal value. This is in contrast to homegrown IT service providers, who are yet to spell out revenue or confirmed orders from the new technology.

Economic Times

37 minutes ago

• Economic Times

US stocks open higher with Trump's Middle East decision in focus

U.S. stocks are drifting higher on Friday in their return to trading following the Juneteenth holiday. ADVERTISEMENT The S&P 500 was up 0.4% in early trading and adding to its modest gain for the week. The Dow Jones Industrial Average was up 162 points, or 0.4%, as of 9:35 am. Eastern time, and the Nasdaq composite was 0.6% higher. Treasury yields were also edging higher in the bond market after President Donald Trump said he will decide within two weeks whether the U.S. military will get directly involved in Israel's fighting with Iran. The window offers the possibility of a negotiated settlement over Iran's nuclear program that could avoid increased fighting. The conflict has sent oil prices yo-yoing because of rising and ebbing fears that it could disrupt the global flow of crude. Iran is a major producer of oil and also sits on the narrow Strait of Hormuz, through which much of the world's crude passes. On Wall Street, Kroger jumped 6.8% to help lead the market after the grocer reported a better profit for the latest quarter than Wall Street had forecast. It also raised its forecast for an underlying measure of revenue for the full year. Chief Financial Officer David Kennerley said it's seeing positive momentum, but it's still seeing an uncertain overall economic environment. CarMax rose 4.6% after the auto dealer reported a stronger profit for the latest quarter than analysts expected. The company said it sold nearly 6% more used autos during the quarter than it did a year earlier. ADVERTISEMENT On the losing end of Wall Street was Smith & Wesson Brands, the maker of guns. It tumbled 15.3% after reporting profit and revenue for the latest quarter that fell just shy of analysts' Financial Officer Deana McPherson said 'persistent inflation, high interest rates, and uncertainty caused by tariff concerns' have been hurting sales for firearms, and the company expects demand in its upcoming fiscal year to be similar to this past year's, depending on how inflation and Trump's tariffs play out. ADVERTISEMENT A spate of companies has been adjusting or even withdrawing their financial forecasts for the year because of all the uncertainty that tariffs are creating for their customers and for their suppliers. Everyone is waiting to see how big the tariffs will ultimately not just corporate America. The Federal Reserve has been keeping its main interest rate on hold this year, with its latest such decision coming earlier this week, because it's waiting to see exactly by how much tariffs will grind down on the economy and push up inflation. ADVERTISEMENT In the bond market, Treasury yields edged higher. The yield on the 10-year Treasury rose to 4.41% from 4.38% late Wednesday. The two-year yield, which more closely tracks expectations for what the Fed will do, was holding at 3.94%.In stock markets abroad, indexes rose across much of Europe after finishing mixed in Asia. ADVERTISEMENT Tokyo's Nikkei 225 index edged 0.2% lower after Japan reported that its core inflation rate, excluding volatile food prices, rose to 3.7% in May, adding to challenges for Prime Minister Shigeru Ishiba's government and the central bank. (You can now subscribe to our ETMarkets WhatsApp channel)